Glenmark shares rise on Salix drug approval

Glenmark will be manufacturing and supplying the drug to Salix for the US market

Ami Shah
Published1 Jan 2013, 07:19 PM IST
Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement. <br /><br />
Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement. (Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement. )

Mumbai: Shares of drug maker Glenmark Pharmaceuticals Ltd rose as much as 3.4% in intra-day trade as its US partner Salix Pharma Inc. received regulatory approval for selling crofelemer, a new drug for treating diarrhoea in HIV/ Aids patients.

add_main_imageGlenmark will be manufacturing and supplying the drug to Salix for the US market.

Crofelemer has been in-licensed from Napo by Salix and Glenmark, which have the right to commercially manufacture and develop the drug in various markets, brokerage Edelweiss Securities said in a Tuesday report.NextMAds

Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement, and the Indian drug maker expects at least $15 million annually in revenue from the sales of crofelemer in the US for the next few years.

The Glenmark stock also had a boost recently after the company’s wholly owned unit signed an agreement with Forest Laboratories Inc. on 24 December to collaborate for the development of mPGES-1 inhibitors to treat chronic inflammatory conditions.

The US-based Forest Lab will pay $6 million upfront to Glenmark and an additional $3 million to support the next phase of development. Forest will make other payments in financial year 2013-14 to support the advancement of the mPGES-1 inhibitors program.

On Tuesday, Glenmark shares, which had jumped 81.5% in 2012, gained 2.3% to close at Rs539.75 on BSE Ltd. The 30-share benchmark Sensex climbed 0.8% to 19,580.81 points.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.MoreLess
First Published:1 Jan 2013, 07:19 PM IST
HomeCompaniesNewsGlenmark shares rise on Salix drug approval

Most Active Stocks

Bharat Electronics

313.50
03:59 PM | 18 JUL 2024
-12.85 (-3.94%)

Oil & Natural Gas Corporation

331.20
03:59 PM | 18 JUL 2024
8.8 (2.73%)

Zee Entertainment Enterprises

142.45
03:59 PM | 18 JUL 2024
-13 (-8.36%)

Tata Steel

166.35
03:56 PM | 18 JUL 2024
-0.7 (-0.42%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

India Cements

344.75
03:54 PM | 18 JUL 2024
21.7 (6.72%)

IDBI Bank

92.19
03:59 PM | 18 JUL 2024
4.27 (4.86%)

Endurance Technologies

2,679.00
03:29 PM | 18 JUL 2024
102.4 (3.97%)

Gillette India

8,002.75
03:29 PM | 18 JUL 2024
275 (3.56%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    75,099.000.00
    Chennai
    74,659.000.00
    Delhi
    74,512.000.00
    Kolkata
    75,539.000.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.76/L0.00
    Kolkata
    104.95/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsCibilPremiumBudget